From owner-freebsd-doc Wed Dec 2 21:57:24 1998 Return-Path: Received: (from majordom@localhost) by hub.freebsd.org (8.8.8/8.8.8) id VAA02704 for freebsd-doc-outgoing; Wed, 2 Dec 1998 21:57:24 -0800 (PST) (envelope-from owner-freebsd-doc@FreeBSD.ORG) Received: from fw1.s-m.co.jp (fw1.s-m.co.jp [202.238.100.114]) by hub.freebsd.org (8.8.8/8.8.8) with ESMTP id VAA02699 for ; Wed, 2 Dec 1998 21:57:17 -0800 (PST) (envelope-from hello3311@msn.com) From: hello3311@msn.com Received: from fw1.s-m.co.jp by fw1.s-m.co.jp (8.8.8+3.0Wbeta7/3.6W-98012210) with SMTP id OAA12667; Thu, 3 Dec 1998 14:56:02 +0900 (JST) Date: Wed, 02 Dec 98 22:52:28 EST To: yudys@worldnet.att.net Subject: SNN Update Message-ID: <359DFE77.4AC9@erols.com> Sender: owner-freebsd-doc@FreeBSD.ORG Precedence: bulk X-Loop: FreeBSD.org SNN is ONLY sent to subscribers who have asked to be on our list. If you wish to unsubscribe please forward a blank e-mail to: j490@usa.net ************************************************** December 2 1998 SNN - UPDATE NUONCOLOGY LABS INC NLAB - OTC BB NuOncology Labs Inc. continues to move up strongly. The stock closed today at $9.72 up 53c on the day to reach another new high. SNN originally profiled NuOncology Labs Inc at $5.46 on July 9 of this year and again at $4.00 on October 25th. This stock is attracting serious investor attention and looks as though it will easily break through the $10 mark by weeks end. SNN expects the market is anticipating either a news release on NLAB's cancer treatment (Arglabin) or possibly the corporate finance side of NuOncology's business. PLEASE NOTE: SNN will be releasing a NEW PROFILE on a company in the WASTE TECHNOLOGY industry in the next 48 hours - watch for your copy. We have reproduced a copy of a letter that was sent out to subscribers of StreetSignals and the Waaco Kid yesterday (Monday December 1st). ****************************************************************** TODAY'S FEATURE: NuOncology Labs (NLAB) ****************************************************************** NuOncology Labs has been featured several times on StreetSignals and in the proceedings of the Waaco Kid since it opened for trading below 6 last quarter. It closed Monday at an all-time high. Momentum indicators have been highly positive during its recent rally, while the stock nearly doubled. Observers of the company suggest that the rally may not be over, and would not be surprised to see a further substantial move over the next few weeks. ****************************************************************** The company's official press releases map out numerous positive trends as NLAB builds out its business plans: In August, NLAB completed the acquisition of all the outstanding and issued shares of NuOncology Labs, Inc. (NuLab), a private Virginia Corporation. The company noted that it now would participate in the multi-billion dollar cancer treatment industry by supporting the research and marketing of a promising cancer treatment along with the delivery of predictive tests for the optimization of contemporary cancer treatment. "Both activities could greatly improve clinical outcomes while reducing treatment costs," said NLAB, "NuLab management will now focus on revenue and market share growth for our oncology laboratory operations and services which provide a full menu of predictive tests on tissue biopsies, including chemosensitivity assays (CSA's), while our scientific team continues development of our lead cancer treatment compound, Arglabin." A few days later, the Company announced additions to its Board of Directors and Management team, culled from experts in oncology research, business development, international commerce, and product marketing. Two weeks later, NLAB began testing and validating the scientific information generated from the Institute of Phytochemistry and the Cancer Curing Hospital, Karaganda, Kazakhstan, on the drug Arglabin. From the official press release: Arglabin, NuOncology Labs' lead cancer treatment compound, was developed in Kazakhstan. Patents have been filed for this plant-derived compound, and it is already approved for cancer treatment in special clinics in Kazakhstan and other republics of the former Soviet Union. Over 200 patients with a variety of cancers have been treated with Arglabin with very promising results and few side effects. Published data shows that Arglabin inhibits or stops the growth of several types of tumors, both alone and in combination with other compounds, more effectively than most current chemotherapy drugs ("Arglabin. Its Structure, Properties, and Usage," Institute of Phytochemistry, Republic of Kazakhstan, 1997). It has none of the severe side effects usually associated with chemotherapy, does not suppress the patient's immune system, and appears to have a very low level of toxicity. Plans have been initiated to develop registration for Arglabin as an ethical pharmaceutical in the United States and other countries outside the former Soviet Union. As well, plans are being developed for clinical trials aimed at securing FDA approval for use of Arglabin for cancer treatment in the U.S. The company then intends to license the technology to a major pharmaceutical company for formal FDA testing, manufacturing, sales and distribution. By September, NLAB found it necessary to move to new facilities, 5 times larger than the former labs. It is estimated that this facility is capable of performing testing to the rate of some 1000 comprehensive predictive profiles per month, as well as providing areas for drug development and general R&D. Perhaps most significant in this path of development is the most recent announcement by NuLab that it has engaged EBI Securities Corp. to provide consulting services and advice to NuOncology Labs concerning business and financial planning, corporate organization and structure, private and public equity and debt financing, acquisitions, mergers and other similar business combinations. ******************************************************************** NLAB, then, has been mapping out clear paths of progress, and appears to have been quietly gathering support for its stock in the past few weeks, without any actual announcements regarding the outcome of the testing and validation trials involving Arglabin. The recent advance in the price of shares appears, however, to suggest that the Street suspects any forthcoming announcements regarding Arglabin could be positive. Trading volume rose significantly during November's rally, suggesting that the Company has attracted added Institutional support. PowerSignals has learned that NLAB will be presenting information to the European investment community in the next 10 days. Unlike other biotech's, NLAB will not be solely dependent on the success of its lead compounds. NLAB intends to establish a series of predictive oncology testing labs utilizing its proprietary technologies. The benefit of predictive testing to patients is clear. NLAB technology will enable doctors to test patients to determine which modes of therapy might work best on any given individual before actually administering a course of treatment, which can be notoriously rife with unpleasant and painful side effects, and still prove the incorrect and ineffective treatment for that person. Naturally, if Arglabin proves as effective in trials as the Company hopes, the revenues derived via licensing the compound to a major pharmaceutical company for formal FDA testing, manufacturing, sales, and distribution could become substantial. Should the Street come to believe that NLAB could turn profitable in its testing operations, and have further proof of the effectiveness of Arglabin as a cancer treatment, the shares of NLAB could be expected to follow the course of numerous other stocks of companies pursuing quality cancer treatments higher. ******************************************************************* The above article is copyright Capital Markets Communica- tions. All Rights Reserved. ******************************************************************* As a subscriber to SNN you have agreed to have read and fully understand the SNN disclaimer located at: http://206.132.179.167/disclaimer1 To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-doc" in the body of the message